CN102813646A - Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations - Google Patents
Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations Download PDFInfo
- Publication number
- CN102813646A CN102813646A CN2012103151305A CN201210315130A CN102813646A CN 102813646 A CN102813646 A CN 102813646A CN 2012103151305 A CN2012103151305 A CN 2012103151305A CN 201210315130 A CN201210315130 A CN 201210315130A CN 102813646 A CN102813646 A CN 102813646A
- Authority
- CN
- China
- Prior art keywords
- homomangiferin
- pharmaceutical composition
- senile dementia
- hypomnesis
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.
Description
Technical field
The present invention relates to the medicinal application field, particularly application and pharmaceutical composition and the preparation of homomangiferin in preparation control senile dementia and hypomnesis medicine.
Background technology
The homomangiferin structure is C-glycoside xanthone chemical compound, full name 1 shown in formula I; 6,7-trihydroxy-3-methoxyl group-2-C-β-D-pyranglucoside is claimed 3-methoxyl group chimonin again; English name homomangiferin claims 1,6 again; 7-trihydroxy-3-methoxy-2-C-β-D-glucopyranosyl-xanthone is present in Anacardiaceae plant Fructus Mangifera Indicae (Mangifera indica L.), the almond plants such as (Mangifera persiciformis C.).
Formula I
Senile dementia is a kind of chronic disease that chronic progressive external central nervous system degeneration pathological changes is caused, and is characteristic with neural mental symptoms such as cognitive dysfunction and abnormality of personality in various degree such as slow development dysmnesia, disorientation, language function obstacle.The morbidity of senile dementia is increased with the growth at age, and the over-65s prevalence is 5-10%; More than 85 years old is 20-50%.Along with the aging of China's population, the sickness rate of senile dementia is continuous ascendant trend.Therefore, the effective control of exploitation medicine for senile dementia is one of the vital task in current drug research field.But the medicine that the radical cure senile dementia up to the present, also do not occur.
Hypomnesis is the brain pathological phenomenon that is caused by many-sided factor, and the main cause of its generation is brain fag and cerebral anoxia.Brain works overloadingly for a long time, and synthetic, the secretion of neurotransmitter all reduce, and have influence on speed and quality that information is transmitted, cause dysmnesia; On the other hand, because big cerebral anoxia can cause that the brain micro-circulation speed slows down; Nutrient substance just can not be by complete oxidation, and metabolism rubbish such as the free radical that produces in metabolism deposition makes neurocyte be in the hypoxic-ischemic state; Cause the acute or chronic injury of neurocyte, thereby influence the activity and the response speed of cerebral neuron, cause the memory path not smooth; Thinking is obstructed, and the knowledge that is accumulated in the human brain can't be extracted and used at short notice.As wire short-circuiting, whole memory path paralysis.Modern society's dog-eat-dog makes people's a large amount of muscle power and mental of overdrawing, and brain overwork has seriously injured people's health level; Simultaneously the old people with advancing age, cerebrum metabolism slows down, the blood supply oxygen supply is not enough, hypomnesis is obvious, as not preventing, also might develop into senile dementia, therefore, need very vigilant with pay attention to.
The pharmacological research of homomangiferin shows that it has multiple biological activity; Application number is that 201110378996.6 Chinese patent discloses the purposes of homomangiferin in preparation control antihyperuricemic disease drug, is specially in preparation and prevents and treats the purposes in the medicine of hyperuricemia and the gout that causes thereof, lithangiuria.This patent research also discloses the effect that homomangiferin can reduce serum uric acid concentration.Research shows that it has the effect of the inhibition serum uric acid similar with xanthine oxidase depressant allopurinol, simultaneously, can obviously improve urine uric acid concentration again, has the uricosuric excretory function similar with the uricosureic agent probenecid.
But up to the present, the purposes of open source literature report homomangiferin in preparation control senile dementia and hypomnesis medicine do not arranged as yet.
Summary of the invention
The technical problem that the present invention will solve provides the application of homomangiferin in preparation control senile dementia and hypomnesis medicine for to treating the problem that lacks highly effective medicine in senile dementia and the hypomnesis at present.
For solving the problems of the technologies described above, technical scheme provided by the invention is:
A kind of suc as formula the purposes of chemical compound shown in the I in preparation senile dementia prevention and cure medicine.
Formula I
A kind of suc as formula the purposes of chemical compound shown in the I in preparation control hypomnesis medicine.
Senile dementia is a kind of chronic disease that chronic progressive external central nervous system degeneration pathological changes is caused, and is characteristic with neural mental symptoms such as cognitive dysfunction and abnormality of personality in various degree such as slow development dysmnesia, disorientation, language function obstacle.The morbidity of senile dementia is increased with the growth at age, and the over-65s prevalence is 5-10%; More than 85 years old is 20-50%.Along with the aging of China's population, the sickness rate of senile dementia is continuous ascendant trend.Therefore, the effective control of exploitation medicine for senile dementia is one of the vital task in current drug research field.
In an embodiment of the present invention, the inventor utilizes the APP transgenic mice formula I chemical compound to be carried out the pharmacological evaluation of treatment and prevention senile dementia and hypomnesis.
Result of study shows; Compare with the normal control group, the number of times that passes through the original platform position in the APP transgene mice model group 3min significantly reduces, and belongs to the four-quadrant time of staying at original platform and significantly reduces; The swimming distance significantly shortens, and points out its ability of learning and memory obviously to reduce.Compare with model group, homomangiferin group mice of the present invention is passed through number of times significantly to be increased, and all significantly increases with the swimming distance in the four-quadrant time of staying, shows that homomangiferin can significantly improve the impaired ability of learning and memory of APP transgenic mice.
Step down test is the test of the disposable passive avoidance response memory function of reflection mice.With model group relatively, homomangiferin group of the present invention obviously prolongs incubation period, shows that homomangiferin is to having the improvement effect than the long term memory function in the impermanent memory of APP transgenic mice.
APP transgenic mice behavioristics is observed from Morris water maze and step down test two aspects, and the APP695V717I transgenic mice significantly descends at 9 monthly age time space ability of learning and memory and disposable passive avoidance response memory ability; The homomangiferin early intervention can obviously be improved the ability of learning and memory that the APP transgenic mice has descended, and its space learning memory and disposable passive avoidance response memory ability are had obvious improvement effect.
Homomangiferin can improve the content of Ach, strengthens the activity of CHAT, suppresses the activity of AchE.Improve aspect indexs such as APP transgenic Model of Dementia pathology, cholinergic system and apoptosis, this possibly be its main curative effect mechanism and action pathway, has the effect of control Alzheimer.
The present invention also provides a kind of pharmaceutical composition, and it comprises chemical compound shown in the formula I and acceptable adjuvant pharmaceutically.
The present invention also provides a kind of aforementioned pharmaceutical compositions dosage form clinically.
As preferably, this pharmaceutical composition dosage form clinically is oral formulations or ejection preparation.
In an embodiment of the present invention, the aforementioned pharmaceutical compositions that provides peroral dosage form clinically is tablet or capsule.
In an embodiment of the present invention, the aforementioned pharmaceutical compositions that provides injection type clinically is injection liquor or lyophilized injectable powder.
The specific embodiment
The invention discloses the application of a kind of homomangiferin in preparation control senile dementia and hypomnesis medicine, those skilled in the art can use for reference this paper content, suitably improve technological parameter and realize.Special needs to be pointed out is that all similarly replace and change apparent to those skilled in the art, they all are regarded as and are included in the present invention.Method of the present invention and application are described through preferred embodiment; The related personnel obviously can change or suitably change and combination methods and applications as herein described in not breaking away from content of the present invention, spirit and scope, realizes and use technology of the present invention.
Technical scheme provided by the invention is:
A kind of suc as formula the purposes of chemical compound shown in the I in preparation senile dementia prevention and cure medicine.
Formula I
A kind of suc as formula the purposes of chemical compound shown in the I in preparation control hypomnesis medicine.
In order to make those skilled in the art understand technical scheme of the present invention better, the present invention is done further detailed description below in conjunction with specific embodiment.
Embodiment 1: the homomangiferin pharmacological evaluation
1 experiment material, reagent and instrument
Laboratory animal: 60 of 3 monthly age APP695V717I transgenic mices (male and female half and half), body weight 17-23g, the cleaning level, 15 of identical genetic background C57BL/6J mices are normal control.Animal licence numbering SCXK capital 2005-0013.
The experiment medicine: positive control drug is selected donepezil hydrochloride for use, and (trade name: aricept), the 5mg/ sheet is pulverized during use, dissolves with distilled water.
Key instrument: DMS-2 type Morris water maze appearance automatic data collection and processing system, STT-2 mice diving tower appearance (or DT-200 diving tower auto testing instrument), BH-2 type biological microscope, DpxView Pro type computer color vision processing system.
2 experimental techniques
2.1 divide into groups and administration
According to random digit (producing random digit) the APP transgenic mice is divided into normal control group, model group, formula I chemical compound group of the present invention and donepezil hydrochloride group (0.65mg/kg/d), 15 every group at random according to SPS S statistical software.Normal group and model group are given the equal-volume distilled water and are irritated stomach, every day 1 time.Each organizes 24 weeks of mouse stomach, carries out behavioristics's experiment during to 9 monthly ages.
2.2 behavioristics's test
2.2.1Morris water maze test
Morris water maze pool diameter 120cm, the dark 50cm in pond.During experiment the pond is divided into four quadrant districts with four equidistant points, in the middle of four-quadrant is positioned at the pool wall and the center of circle, places the lucite platform.In the pond, add water, the about 20cm of the depth of water, the water surface exceeds platform surface 0.5cm; Water temperature 25+1 ℃, inject milk powder, mixing; Make water become opaque milky, reach the animal vision and can't distinguish the purpose that has or not platform in the pond, and make the activity that function is successfully followed the tracks of mice of calculating.Test is carried out in sound damping room, and various experimental conditions such as position, pond, light source position and intensity remain unchanged in whole experiment, come the locating platform position for mice.
Test program comprises: (1) orientation navigation experiment: be used for measuring the learning and memory ability of animal at water maze.
Carry out every day 1 time, trained continuously 5 days.Remove platform the 5th day afternoon; Optional place of entry; Mice is put into the pond towards pool wall, and camera system writes down the number of times in turnover original platform district in the mice 3min automatically and belongs to four-quadrant swimming time and the index of distance as evaluation learning and memory of little mouse achievement at original platform.
2.2.2 step down test
Diving tower appearance experimental box links to each other with the computer automatic production record.During experiment mice is put into diving tower appearance experimental box, the 5min that conforms puts down mice gently on diving tower afterwards; And with the energising of copper grid, can be shocked by electricity when diving tower jumps off extremity contact copper grid when mice, normal avoidance response is to jump onto diving tower to return the place of safety; Escape electric shock; So learn 5min, and write down the electric shock number of times (errors number) in this 5min, as school grade.Carry out the memory ability test behind the 24h; Mice is placed on the diving tower; The record mice from rest on the diving tower to jump off for the first time the time of being shocked by electricity be incubation period with 5min in errors number (the mice extremity contact the number of times of copper grid electric shock simultaneously), with this evaluation index as memory function.
2.3 brain tissue sample handles
Mice is after the test of last behavioristics, and fasting 12h carries out cerebral tissue and serum and draws materials.Eyeball was got blood after each organized mouse anesthesia, centrifugal (2500r/min, 15min), separation of serum maintains the temperature at 4 ℃ in order to follow-up index detection; Broken end is got full brain fast at low temperatures, with ice-cold normal saline cleaning bloodstain, blots with filter paper, weighs.6 of every group of picked at random drop in 4% paraformaldehyde solution fixedly 24h above (4 ℃), change the back fixative afterwards, treat can carry out frozen section after the cerebral tissue sinking, or FFPE, carry out pathology and immunohistochemical staining.All the other (except that small dose group is 7, other are 8) mices are rapid selective separating and Hippocampus (carrying out on the ice cream) respectively, and each adds 2ml normal saline (distilled water) homogenate, and the low-temperature and high-speed centrifuge is centrifugal, and separation of supernatant is used for tissue content and measures.In irritating the stomach process, dead 1 of Chinese medicine small dose group; In step down test, Western medicine group has 1 to get an electric shock and die.
3 experimental results
3.1 homomangiferin is to the influence of APP transgenic mice space learning memory ability
Compare with normal group, model group is passed through original platform position number of times, four-quadrant swimming time and distance and is all significantly reduced in the Morris water maze.After each administration group treatment, in the Morris water maze, pass through original platform position number of times, four-quadrant swimming time and distance and all significantly increase than model group.The result sees table 1.
Table 1 homomangiferin is remembered APP transgenic mice space learning
The influence of ability (x ± s, n=15)
3.2 homomangiferin is to the influence of the disposable avoidance response memory function of APP transgenic mice
In step down test, the model group errors number obviously increases than normal group, and each treatment group errors number obviously descends than normal group.With normal group relatively, obviously shorten the incubation period of model group, and donepezil hydrochloride group and homomangiferin group are obviously prolonged incubation period.The result sees table 2.
Table 2 homomangiferin to the influence of the disposable avoidance response memory function of APP transgenic mice (x ± s, n=15)
3.3 homomangiferin is to the influence of acetylcholine, choline acetyltransterase and Acetylcholinesterase content in the APP mice Hippocampus
With compared with normal, the content of Ach, CHAT obviously reduces and AchE content obviously improves in the model group Hippocampus; The donepezil hydrochloride group is compared with model group with the homomangiferin group, and the content of Ach, CHAT obviously improves in the Hippocampus, and AchE content obviously reduces.Explain that homomangiferin can effectively improve the content of Ach in the Hippocampus, strengthen the activity of CHAT in the Hippocampus, suppress the activity of AchE in the Hippocampus, thereby improve aspect indexs such as APP transgenic Model of Dementia pathology, cholinergic system and apoptosis.This possibly be its mechanism of action and action pathway with control Alzheimer.The result sees table 3.
Table 3 homomangiferin to the influence of APP transgenic mice Hippocampus Ach, AchE, CHAT content (x ± s, n=15)
3.4 homomangiferin is to the influence of acetylcholine, choline acetyltransterase and Acetylcholinesterase content in the cortex
With compared with normal, the content of Ach, CHAT obviously reduces and AchE content obviously improves in the model group cortex; The donepezil hydrochloride group is compared with model group with the homomangiferin group, and the content of Ach, CHAT obviously improves in the cortex, and AchE content obviously reduces.Explain that homomangiferin can effectively improve the content of Ach in the cortex, strengthen the activity of CHAT in the cortex, suppress the activity of AchE in the cortex, thereby improve aspect indexs such as APP transgenic Model of Dementia pathology, cholinergic system and apoptosis.This possibly be its mechanism of action and action pathway with control Alzheimer.The result sees table 4.
Table 4 homomangiferin to the influence of APP transgenic mice cortex Ach, AchE, CHAT content (x ± s, n=15)
4 conclusions
The APP transgenic mice is to utilize the method for microinjection that app gene or genetic fragment are integrated in the genome of mice, makes the mice brain express app gene.Through APP albumen overexpression in brain, A β produces increase, causes the neuron excitotoxicity effect, injured mice ability of learning and memory, and gathering and formation of deposits senile plaque, thus cause mice senile dementia transgenic animal model.
This result of study shows; Compare with the normal control group, the number of times that passes through the original platform position in the APP transgene mice model group 3min significantly reduces, and belongs to the four-quadrant time of staying at original platform and significantly reduces; The swimming distance significantly shortens, and points out its ability of learning and memory obviously to reduce.Compare with model group, homomangiferin group mice of the present invention is passed through number of times significantly to be increased, and all significantly increases with the swimming distance in the four-quadrant time of staying, shows that homomangiferin can significantly improve the impaired ability of learning and memory of APP transgenic mice.
Step down test is the test of the disposable passive avoidance response memory function of reflection mice.With model group relatively, homomangiferin group of the present invention obviously prolongs incubation period, shows that homomangiferin is to having the improvement effect than the long term memory function in the impermanent memory of APP transgenic mice.
APP transgenic mice behavioristics is observed from Morris water maze and step down test two aspects, and the APP695V717I transgenic mice significantly descends at 9 monthly age time space ability of learning and memory and disposable passive avoidance response memory ability; The homomangiferin early intervention can obviously be improved the ability of learning and memory that the APP transgenic mice has descended, and its space learning memory and disposable passive avoidance response memory ability are had obvious improvement effect.
Homomangiferin can improve the content of Ach, strengthens the activity of CHAT, suppresses the activity of AchE.Improve aspect indexs such as APP transgenic Model of Dementia pathology, cholinergic system and apoptosis, this possibly be its main curative effect mechanism and action pathway, has the effect of control Alzheimer.
Embodiment 2: pharmaceutical composition
Embodiment 3: pharmaceutical composition
Embodiment 4: pharmaceutical composition
Embodiment 5: pharmaceutical composition
Embodiment 6: pharmaceutical composition
Embodiment 7: pharmaceutical composition
This pharmaceutical composition is a tablet, with chemical compound provided by the invention, starch, microcrystalline Cellulose, carboxymethyl starch sodium and magnesium stearate, mixes back tabletting on tablet machine, promptly gets.
Embodiment 8: pharmaceutical composition
This pharmaceutical composition is a tablet, with chemical compound provided by the invention, starch, microcrystalline Cellulose, carboxymethyl starch sodium and magnesium stearate, mixes back tabletting on tablet machine, promptly gets.
Embodiment 9: pharmaceutical composition
This pharmaceutical composition is a tablet, with chemical compound provided by the invention, starch, microcrystalline Cellulose, carboxymethyl starch sodium and magnesium stearate, mixes back tabletting on tablet machine, promptly gets.
Embodiment 10: pharmaceutical composition
Homomangiferin chemical compound 5% provided by the invention
Dried starch 90%
Magnesium stearate 5%
This pharmaceutical composition is a capsule, with chemical compound provided by the invention, dried starch and magnesium stearate, is packed into after the mixing in the hard gelatin capsule, promptly gets.
Embodiment 11: pharmaceutical composition
Homomangiferin chemical compound 12% provided by the invention
Dried starch 73%
Magnesium stearate 15%
This pharmaceutical composition is a capsule, with chemical compound provided by the invention, dried starch and magnesium stearate, is packed into after the mixing in the hard gelatin capsule, promptly gets.
Embodiment 12: pharmaceutical composition
The present invention provides homomangiferin chemical compound 15%
Dried starch 65%
Magnesium stearate 20%
This pharmaceutical composition is a capsule, with chemical compound provided by the invention, dried starch and magnesium stearate, is packed into after the mixing in the hard gelatin capsule, promptly gets.
Embodiment 13: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 14: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 15: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 16: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 17: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 18: pharmaceutical composition
This pharmaceutical composition adds the ethanol stirring and dissolving for the injection liquor with chemical compound provided by the invention, adds sodium chloride and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption; Add water for injection to ormal weight, the microporous filter membrane filtration props up embedding by 1mL/; 100 ℃ of moist heat sterilization 20min, qualified through lamp inspection, promptly get.
Embodiment 19: pharmaceutical composition
This pharmaceutical composition is a lyophilized injectable powder, and chemical compound provided by the invention is added the ethanol stirring and dissolving, adds sodium chloride, mannitol and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption, adds water for injection to ormal weight; The microporous filter membrane filtration props up packing by 4mL/, lyophilization; Encapsulation through being up to the standards, promptly gets.
Embodiment 20: pharmaceutical composition
This pharmaceutical composition is a lyophilized injectable powder, and chemical compound provided by the invention is added the ethanol stirring and dissolving, adds sodium chloride, mannitol and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption, adds water for injection to ormal weight; The microporous filter membrane filtration props up packing by 4mL/, lyophilization; Encapsulation through being up to the standards, promptly gets.
Embodiment 21: pharmaceutical composition
This pharmaceutical composition is a lyophilized injectable powder, and chemical compound provided by the invention is added the ethanol stirring and dissolving, adds sodium chloride, mannitol and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption, adds water for injection to ormal weight; The microporous filter membrane filtration props up packing by 4mL/, lyophilization; Encapsulation through being up to the standards, promptly gets.
Embodiment 22: pharmaceutical composition
This pharmaceutical composition is a lyophilized injectable powder, and chemical compound provided by the invention is added the ethanol stirring and dissolving, adds sodium chloride, mannitol and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption, adds water for injection to ormal weight; The microporous filter membrane filtration props up packing by 4mL/, lyophilization; Encapsulation through being up to the standards, promptly gets.
Embodiment 23: pharmaceutical composition
This pharmaceutical composition is a lyophilized injectable powder, and chemical compound provided by the invention is added the ethanol stirring and dissolving, adds sodium chloride, mannitol and an amount of water for injection, stirs; Add 0.1% pin and use activated carbon, decarburization is filtered in absorption, adds water for injection to ormal weight; The microporous filter membrane filtration props up packing by 4mL/, lyophilization; Encapsulation through being up to the standards, promptly gets.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; Can also make some improvement and retouching, these improvement and retouching also should be regarded as protection scope of the present invention.
Claims (10)
1. one kind suc as formula the purposes of chemical compound shown in the I in preparation senile dementia prevention and cure medicine.
Formula I
2. one kind suc as formula the purposes of chemical compound shown in the I in preparation control hypomnesis medicine.
3. a pharmaceutical composition that is used for senile dementia prevention and cure or hypomnesis is characterized in that, comprises chemical compound and acceptable accessories shown in the formula I.
4. one kind like the said pharmaceutical composition of claim 3 dosage form clinically.
5. dosage form according to claim 4 is characterized in that, is oral formulations or ejection preparation.
6. dosage form according to claim 5 is characterized in that, said oral formulations is tablet or capsule.
7. dosage form according to claim 6 is characterized in that, said tablet consists of by mass ratio:
8. dosage form according to claim 5 is characterized in that, said ejection preparation is injection liquor or lyophilized injectable powder.
9. dosage form according to claim 8 is characterized in that, said injection liquor consists of by mass ratio:
10. dosage form according to claim 8 is characterized in that, said lyophilized injectable powder consists of by mass ratio:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210315130.5A CN102813646B (en) | 2012-08-30 | 2012-08-30 | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210315130.5A CN102813646B (en) | 2012-08-30 | 2012-08-30 | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102813646A true CN102813646A (en) | 2012-12-12 |
| CN102813646B CN102813646B (en) | 2014-07-30 |
Family
ID=47298333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210315130.5A Active CN102813646B (en) | 2012-08-30 | 2012-08-30 | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102813646B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069062A (en) * | 2013-03-29 | 2014-10-01 | 昆明制药集团股份有限公司 | Hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as preparation method and application thereof |
| WO2020061809A1 (en) * | 2018-09-26 | 2020-04-02 | 泰州丹鼎生物科技有限公司 | Applications of 1,2,3,6,7-pentamethoxybenzophenone in preparing medicament for preventing and treating hippocampal neuron-related diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351835A (en) * | 2011-11-11 | 2012-02-15 | 昆明制药集团股份有限公司 | Mangiferin aglycone crystal forms, and composition, preparation method and application thereof |
| CN102499934A (en) * | 2011-11-24 | 2012-06-20 | 昆明制药集团股份有限公司 | Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia |
-
2012
- 2012-08-30 CN CN201210315130.5A patent/CN102813646B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351835A (en) * | 2011-11-11 | 2012-02-15 | 昆明制药集团股份有限公司 | Mangiferin aglycone crystal forms, and composition, preparation method and application thereof |
| CN102499934A (en) * | 2011-11-24 | 2012-06-20 | 昆明制药集团股份有限公司 | Application of 3-methoxy xanthone compound in preparation of medicament for preventing and treating hyperuricemia |
Non-Patent Citations (1)
| Title |
|---|
| KANGSIK JUNG，ET AL: "Mangiferin Ameliorates Scopolamine-Induced Learning Deficits in Mice", 《BIOLOGICAL AND PHARMACEUTICAL BULLETIN》, vol. 32, no. 2, 28 February 2009 (2009-02-28) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069062A (en) * | 2013-03-29 | 2014-10-01 | 昆明制药集团股份有限公司 | Hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as preparation method and application thereof |
| CN104069062B (en) * | 2013-03-29 | 2017-01-25 | 昆药集团股份有限公司 | Hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as preparation method and application thereof |
| WO2020061809A1 (en) * | 2018-09-26 | 2020-04-02 | 泰州丹鼎生物科技有限公司 | Applications of 1,2,3,6,7-pentamethoxybenzophenone in preparing medicament for preventing and treating hippocampal neuron-related diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102813646B (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Silibinin ameliorates STZ-induced impairment of memory and learning by up-regulating insulin signaling pathway and attenuating apoptosis | |
| CN102786414B (en) | Compound for treating and/or preventing neurodegenerative related disease | |
| CN102755341A (en) | Application of acteoside in preparing medicine for treating alzheimer disease | |
| CN102813646B (en) | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations | |
| TW202033212A (en) | Use of agarwood extract | |
| CN102397279A (en) | Application of friedelin-3 beta-alcohol to preparation of vascular dementia-resisting medicaments | |
| CN104042720B (en) | There is the Chinese medicine and application thereof of preventing and treating diabetes complicated depression | |
| CN102935100A (en) | Preparation method and applications of queen lagerstroemia folium apocyni veneti general flavones | |
| CN102784160B (en) | Application of forsythin to preparation of medicine for improving cognitive function and treating Alzheimer's diseases | |
| CN104069263A (en) | A preparation used for treating Alzheimer's disease and a preparing method thereof | |
| CN103040905B (en) | Herba arenariae kansuensis or the purposes of its extract in the antidotal medicine of preparation or health food | |
| CN102000148B (en) | Application of scutelaria baicalemis and baicalin in preparing medicament for improving learning memory and treating Alzheimer's disease | |
| CN106344609A (en) | Application of ozonized oil in preventing and controlling nervous system diseases | |
| CN109528719B (en) | Application of vinpocetine in preparation of medicine for preventing and/or treating altitude disease caused by acute altitude advancement | |
| CN104130232B (en) | The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition | |
| CN111317746B (en) | Application of fullerene structure in preparation of drug for treating Alzheimer disease | |
| CN116270901B (en) | Chinese herbal compound and pharmaceutical composition thereof | |
| CN113350488B (en) | Application of oral hypoglycemic peptide OHP in preparation of medicine for resisting neurodegenerative diseases | |
| CN102028674A (en) | Application of needle-leaved polyprenol in preparing medicines for preventing and treating Alzheimer disease | |
| CN114469967B (en) | Application of atractyloside A and derivatives thereof in preparation of anxiolytic and antidepressant drugs | |
| CN107569506A (en) | Ligustrum lucidum Ait, Rhoifolin composition and application thereof | |
| Shouye et al. | A research on the erupted fetal diseases caused by traditional Chinese drugs—discussion from the issue that Chinese Goldthread Rhizome is prohibited in Singapore | |
| CN107536841A (en) | Ligustrum lucidum Ait, Rhoifolin, Hyperoside composition and application thereof | |
| CN113694055B (en) | Application of agalloch eaglewood tetrol in preparing medicine for treating vascular dementia | |
| CN101642465A (en) | Application of Kadsura heteroclite (Roxb.) Craib polysaccharide of Guangdong province for preparing medicaments for preventing and/or treating senile dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: KPC CO., LTD. Free format text: FORMER NAME: KUNMING PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 650106 Kunming science and Technology Industrial Development Zone, Yunnan Province Road No. 166 Patentee after: Kun Yao Group Plc Address before: 650106 Kunming science and Technology Industrial Development Zone, Yunnan Province Road No. 166 Patentee before: Kunming Pharmaceutical Industry Group Corp., Ltd. |